Detection and localization of surgically resectable cancers with a multi-analyte blood test
Menée auprès de 812 témoins et 1 005 patients atteints d'un cancer non métastatique de l'ovaire, du foie, de l'estomac, du pancréas, de l'œsophage, du poumon, du sein, du côlon ou du rectum, cette étude évalue la sensibilité et la spécificité d'un test sanguin, mesurant le niveau de plusieurs biomarqueurs et recherchant des mutations dans l'ADN circulant, pour détecter et localiser précocement des tumeurs
Earlier detection is key to reducing cancer deaths. Here we describe a blood test that can detect eight common cancer types through assessment of the levels of circulating proteins and mutations in cell-free DNA. We applied this test, called CancerSEEK, to 1,005 patients with non-metastatic, clinically detected cancers of the ovary, liver, stomach, pancreas, esophagus, colorectum, lung, or breast. CancerSEEK tests were positive in a median of 70% of the eight cancer types. The sensitivities ranged from 69% to 98% for the detection of five cancer types (ovary, liver, stomach, pancreas, and esophagus) for which there are no screening tests available for average-risk individuals. The specificity of CancerSEEK was > 99%: only 7 of 812 healthy controls scored positive. In addition, CancerSEEK localized the cancer to a small number of anatomic sites in a median of 83% of the patients.
Science , résumé, 2017